Targeting mitochondrial complexes for cancer therapy

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Mitochondrial electron transport chain (ETC) complexes I-IV are crucial for cancer cell energy and biosynthesis.
• Inhibiting these complexes is a promising strategy to block cancer cell survival.

Purpose of the Study:

• To review current findings on ETC complex inhibition for cancer treatment.
• To explore bioenergetic disruption and novel therapeutic strategies like photodynamic therapy (PDT).
• To highlight the role of AI and nanotechnologies in developing ETC-targeted cancer drugs.

Main Methods:

• In silico, in vitro, and in vivo studies on ETC complex inhibition were reviewed.
• Analysis of bioenergetic disruption mechanisms.
• Exploration of therapeutic strategies including PDT, small molecules, repurposed drugs, AI, and nanotechnologies.

Main Results:

• Inhibition of ETC complexes effectively blocks cancer cell survival.
• Photodynamic therapy (PDT) and other novel strategies show promise.
• AI and nanotechnologies can accelerate the discovery of ETC-targeted anticancer drugs.
• Targeting ETC complexes can be integrated into precision medicine.

Conclusions:

• Mitochondrial ETC complexes are viable targets for developing novel anticancer drugs.
• A combination of bioenergetic disruption, innovative therapies, and AI-driven approaches can enhance cancer treatment.
• Precision medicine strategies can leverage ETC dependencies for personalized cancer therapy.